Lisa Rossius

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker et al. · The Lancet Oncology · 2014 · 1.7K citations

Medicine, Oncology, Pharmacology +9

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial

Sebastian Stintzing, Dominik Paul Modest, Lisa Rossius et al. · The Lancet Oncology · 2016 · 418 citations

Medicine, Oncology, Pharmacology +14

Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

Sebastian Stintzing, Andreas Jung, Lisa Rossius et al. · Journal of Clinical Oncology · 2014 · 97 citations

Medicine, Oncology, Pharmacology +17